SCHEMBL2946980

SCHEMBL2946980

O=C1C(Cc2ccc3c(c2)OCO3)CCCN1Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
TSHR P16473 3/20 0.52
SIGMAR1 Q99720 2/20 0.48
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
FAAH O00519 2/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 2/20 0.46
HSD17B10 Q99714 1/20 0.46
DYRK1A Q13627 1/20 0.46
KMT2A Q03164 2/20 0.45
CYP2D6 P10635 2/20 0.45
PKM P14618 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP3A4 P08684 1/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A1 P30531 1/20 0.45
SLC6A3 Q01959 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6732065 0.83 HSD11B1 (0.55) ALDH1A1KMT2AMEN1
SCHEMBL14177658 0.82 ALDH1A1 (0.60) ALDH1A1TSHRSIGMAR1LMNAGAA
SCHEMBL107297 0.75 CYP3A4 (0.55) ALDH1A1TSHRGAAHSD17B10KMT2A
SCHEMBL2942193 0.74 TSHR (0.58) ALDH1A1TSHRSIGMAR1LMNAKMT2A
SCHEMBL6733710 0.74 HSD11B1 (0.57) ALDH1A1KMT2ACYP2D6MEN1
SCHEMBL7442356 0.73 L3MBTL1 (0.49) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL4522790 0.73 L3MBTL1 (0.43) ALDH1A1TSHRSIGMAR1LMNAKMT2A
SCHEMBL14177723 0.73 ALDH1A1 (0.47) ALDH1A1TSHRGAAHSD17B10DYRK1A
SCHEMBL14177722 0.73 ALDH1A1 (0.47) ALDH1A1TSHRGAAHSD17B10DYRK1A
SCHEMBL14177626 0.72 MAPT (0.51) ALDH1A1SIGMAR1GAACMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754719-B2 Substituted piperidine derivatives as somatostatin SST1 receptor antagonists NOVARTIS AG (CH) 2010-07-13 US disclosed
EP-1909792-B1 SUBSTITUTED PIPERIDINE DERIVATIVES AS SOMATOSTATIN SST1 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2009-09-02 EP disclosed
US-20080255142-A1 Substituted Piperidine Derivatives as Somatostatin Sst1 Receptor Antagonists NOVARTIS AG (CH) 2008-10-16 US disclosed
EP-1909792-A1 SUBSTITUTED PIPERIDINE DERIVATIVES AS SOMATOSTATIN SST1 RECEPTOR ANTAGONISTS Novartis AG (CH) 2008-04-16 EP disclosed
WO-2007009662-A1 SUBSTITUTED PIPERIDINE DERIVATIVES AS SOMATOSTATIN SST1 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255142-A1 Substituted Piperidine Derivatives as Somatostatin Sst1 Receptor Antagonists SSTR1, SSTR2, SSTR3 ALDH1A1 2021/4885TSHR 24/4885SIGMAR1 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.